Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-RAD301
- Development stage
- Phase 1
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
**68Ga-RAD301** is an investigational diagnostic radiopharmaceutical consisting of a peptide conjugate radiolabeled with gallium-68 (68Ga), developed for PET imaging of **αvβ6-integrin** expression in carcinomas, particularly pancreatic ductal adenocarcinoma (PDAC). Integrin αvβ6 is a cell-surface receptor highly expressed in many epithelial cancers, where its presence correlates with tumor invasion, metastatic growth, and poor prognosis. 68Ga-RAD301 binds to αvβ6-integrin with high specificity, enabling non-invasive visualization of primary and metastatic lesions via PET/CT with high tumor-to-background ratios. The radioisotope conjugate is administered intravenously at doses of 150±50 MBq (approx. 4 mCi) and undergoes serial imaging sessions to assess biodistribution, radiation dosimetry, and safety. Clinical studies have shown strong imaging efficacy and no reported adverse safety issues. In May 2024, it was granted FDA orphan drug designation for pancreatic cancer imaging.
- Brand names
- 68Ga-RAD30168Ga-Trivehexin
- Other names
- 68Ga-RAD30168Ga-TrivehexinGa68-TrivehexinGa-68-TrivehexinGa 68-TrivehexinGa68-RAD301Ga-68-RAD301Ga 68-RAD301
02
Targets
αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on 68Ga-RAD301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-RAD301.